Results 141 to 150 of about 332,155 (265)

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

Long‐term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real‐world cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved cystic fibrosis (CF) outcomes. However, its long‐term impact on nutrition, metabolism and liver health remains underexplored. We assessed 30‐month changes in pulmonary, nutritional, metabolic and inflammatory markers in people with CF (PwCF) homozygous for F508del.
Nicola Perrotta   +5 more
wiley   +1 more source

Completion vs. early discontinuation of chemotherapy and the impact on 5‐year all‐cause mortality in women treated for early‐stage breast cancer from 2015 to 2020: A cohort study using a target trial emulation approach

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Chemotherapy is given for early‐stage breast cancer; however, some patients discontinue before completing all planned cycles. This study investigated the impact of early chemotherapy discontinuation on treatment outcomes. Methods This retrospective cohort study used a target trial emulation framework to conduct a causal analysis of the all‐
Luke Steventon   +9 more
wiley   +1 more source

One size does not fit all: Qualitative interviews with individuals with overweight or obesity and healthcare providers on navigating and supporting weight management. [PDF]

open access: yesObes Pillars
Stanford FC   +11 more
europepmc   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad   +4 more
wiley   +1 more source

Making teaching more attractive: Promising evidence of impact from Australia

open access: yesBritish Educational Research Journal, EarlyView.
Abstract Sustaining teaching as a respected and attractive profession is more critical than ever, particularly as teachers' work becomes increasingly shaped by standardisation and accountability—conditions that have shown minimal positive impact while eroding the professional agency essential to job satisfaction.
Jennifer M. Gore   +5 more
wiley   +1 more source

Mother-child dyads double burden of malnutrition and associated factors in Burkina Faso. [PDF]

open access: yesPublic Health Nutr
Lanou HB   +5 more
europepmc   +1 more source

Designing the MyoFusion Media: A Serum‐Free Medium Optimized for Bovine Satellite Cell Differentiation

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Cultivated meat production requires efficient differentiation of muscle progenitor cells into myotubes without relying on animal‐derived serum, which poses ethical and scalability challenges. This study aimed to develop a chemically defined, serum‐free medium optimized for bovine satellite cell differentiation.
Aysenaz Tavsanli   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy